Angiotensinogen: a new era beyond lactate as a biomarker?

IF 8.8 1区 医学 Q1 CRITICAL CARE MEDICINE Critical Care Pub Date : 2024-12-02 DOI:10.1186/s13054-024-05164-y
Yanfei Shen, Xinyuan Ding
{"title":"Angiotensinogen: a new era beyond lactate as a biomarker?","authors":"Yanfei Shen, Xinyuan Ding","doi":"10.1186/s13054-024-05164-y","DOIUrl":null,"url":null,"abstract":"<p>Dear editor</p><p>In a recent brief report [1], Dr.Chappell and colleagues compared the predictive value of angiotensinogen, renin, and lactate for 30-day mortality in patients with sepsis or septic shock. The study included a total of 103 sepsis patients. The results showed that serum angiotensinogen concentration had a stronger association with mortality than either serum renin or lactate, suggesting that angiotensinogen may serve as a clinical predictor superior to lactate. We believe several points should be noted when interpreting these findings.</p><p>First, lactate is widely recognized as an important biomarker in critically ill patients, primarily reflecting an imbalance in tissue oxygen supply and consumption, which is commonly used to assess tissue perfusion and disease severity in septic shock. However, although this study included patients with sepsis or septic shock, we observed that the baseline systolic blood pressure in both the survival and non-survival groups was approximately 100 mmHg (survival group: 102.1 ± 23.5; non-survival group: 106.0 ± 21.9, <i>p</i> = 0.464), indicating that these patients were not in a state of severe shock or, at the very least, retained a degree of hemodynamic stability. Additionally, the baseline lactate levels were also relatively low and similar between the two groups (survival group: 2.6 [1.8–3.8]; non-survival group: 2.2 [1.6–6.1], <i>p</i> = 0.629). This raises the question of whether the study sample might skew toward a less severe sepsis population, which could influence the relative performance of angiotensinogen and lactate as predictive markers (as patients with relatively stable circulation tend to have normal lactate levels).</p><p>Moreover, this study found no significant difference in survival analysis between high and low lactate groups, which is inconsistent with previous findings in septic shock [2,3,4]. This lack of difference may be attributed to specific characteristics of the patient cohort or sample heterogeneity, which may limit the generalizability of this study’s findings to sepsis patients.</p><p>Future studies with larger, more diverse sepsis cohorts are needed to validate these findings and further explore the potential of angiotensinogen as a routine prognostic marker in sepsis or septic shock. Given lactate’s established role in assessing sepsis severity and predicting outcomes, future research should also investigate whether angiotensinogen can complement lactate or other established biomarkers to provide additional prognostic value. Also, longitudinal studies could help clarify the dynamic changes in angiotensinogen levels over time and their correlation with patient outcomes, offering a more comprehensive understanding of angiotensinogen’s role in the complex pathophysiology of sepsis.</p><p>Finally, we extend our gratitude to Dr. Chappell and colleagues for their valuable work, and we hope our perspectives contribute to a deeper understanding of these findings.</p><p>No datasets were generated or analysed during the current study.</p><ol data-track-component=\"outbound reference\" data-track-context=\"references section\"><li data-counter=\"1.\"><p>Chappell MC, Schaich CL, Busse LW, Martin GS, Sevransky JE, Hinson JK, Khanna AK, Vitamin C. Stronger association of intact angiotensinogen with mortality than lactate or renin in critical illness: post-hoc analysis from the VICTAS trial. Crit Care. 2024;28(1):333.</p><p>Article PubMed PubMed Central Google Scholar </p></li><li data-counter=\"2.\"><p>Zampieri FG, Damiani LP, Bakker J, Ospina-Tascon GA, Castro R, Cavalcanti AB, Hernandez G. Effects of a Resuscitation Strategy Targeting Peripheral Perfusion Status versus serum lactate levels among patients with septic shock. A bayesian reanalysis of the ANDROMEDA-SHOCK Trial. Am J Respir Crit Care Med. 2020;201(4):423–9.</p><p>Article CAS PubMed Google Scholar </p></li><li data-counter=\"3.\"><p>Han X, Edelson DP, Snyder A, Pettit N, Sokol S, Barc C, Howell MD, Churpek MM. Implications of Centers for Medicare &amp; Medicaid Services Severe Sepsis and septic shock early management bundle and initial lactate measurement on the management of Sepsis. Chest. 2018;154(2):302–8.</p><p>Article PubMed PubMed Central Google Scholar </p></li><li data-counter=\"4.\"><p>Houwink AP, Rijkenberg S, Bosman RJ, van der Voort PH. The association between lactate, mean arterial pressure, central venous oxygen saturation and peripheral temperature and mortality in severe sepsis: a retrospective cohort analysis. Crit Care. 2016;20:56.</p><p>Article PubMed PubMed Central Google Scholar </p></li></ol><p>Download references<svg aria-hidden=\"true\" focusable=\"false\" height=\"16\" role=\"img\" width=\"16\"><use xlink:href=\"#icon-eds-i-download-medium\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"></use></svg></p><p>Not applicable.</p><p>None.</p><h3>Authors and Affiliations</h3><ol><li><p>Department of Intensive Care, Zhejiang Hospital, No. 1229, Gudun Road, Hangzhou, 310013, Zhejiang, People’s Republic of China</p><p>Yanfei Shen</p></li><li><p>The Second Clinical Medical College of Zhejiang, Chinese Medical University, Hangzhou, 310053, Zhejiang, China</p><p>Xinyuan Ding</p></li></ol><span>Authors</span><ol><li><span>Yanfei Shen</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Xinyuan Ding</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li></ol><h3>Contributions</h3><p>Dr. Xinyuan Ding raised the clinical issue and Dr. Yanfei Shen wrote the letter. All authors have reviewed and approved the letter.</p><h3>Corresponding author</h3><p>Correspondence to Yanfei Shen.</p><h3>Ethics approval and consent to participate</h3>\n<p>Not applicable.</p>\n<h3>Consent for publication</h3>\n<p>Not applicable.</p>\n<h3>Competing interests</h3>\n<p>The authors declare no competing interests.</p><h3>Publisher’s note</h3><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p><p><b>Open Access</b> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.</p>\n<p>Reprints and permissions</p><img alt=\"Check for updates. Verify currency and authenticity via CrossMark\" height=\"81\" loading=\"lazy\" src=\"data:image/svg+xml;base64,<svg height="81" width="57" xmlns="http://www.w3.org/2000/svg"><g fill="none" fill-rule="evenodd"><path d="m17.35 35.45 21.3-14.2v-17.03h-21.3" fill="#989898"/><path d="m38.65 35.45-21.3-14.2v-17.03h21.3" fill="#747474"/><path d="m28 .5c-12.98 0-23.5 10.52-23.5 23.5s10.52 23.5 23.5 23.5 23.5-10.52 23.5-23.5c0-6.23-2.48-12.21-6.88-16.62-4.41-4.4-10.39-6.88-16.62-6.88zm0 41.25c-9.8 0-17.75-7.95-17.75-17.75s7.95-17.75 17.75-17.75 17.75 7.95 17.75 17.75c0 4.71-1.87 9.22-5.2 12.55s-7.84 5.2-12.55 5.2z" fill="#535353"/><path d="m41 36c-5.81 6.23-15.23 7.45-22.43 2.9-7.21-4.55-10.16-13.57-7.03-21.5l-4.92-3.11c-4.95 10.7-1.19 23.42 8.78 29.71 9.97 6.3 23.07 4.22 30.6-4.86z" fill="#9c9c9c"/><path d="m.2 58.45c0-.75.11-1.42.33-2.01s.52-1.09.91-1.5c.38-.41.83-.73 1.34-.94.51-.22 1.06-.32 1.65-.32.56 0 1.06.11 1.51.35.44.23.81.5 1.1.81l-.91 1.01c-.24-.24-.49-.42-.75-.56-.27-.13-.58-.2-.93-.2-.39 0-.73.08-1.05.23-.31.16-.58.37-.81.66-.23.28-.41.63-.53 1.04-.13.41-.19.88-.19 1.39 0 1.04.23 1.86.68 2.46.45.59 1.06.88 1.84.88.41 0 .77-.07 1.07-.23s.59-.39.85-.68l.91 1c-.38.43-.8.76-1.28.99-.47.22-1 .34-1.58.34-.59 0-1.13-.1-1.64-.31-.5-.2-.94-.51-1.31-.91-.38-.4-.67-.9-.88-1.48-.22-.59-.33-1.26-.33-2.02zm8.4-5.33h1.61v2.54l-.05 1.33c.29-.27.61-.51.96-.72s.76-.31 1.24-.31c.73 0 1.27.23 1.61.71.33.47.5 1.14.5 2.02v4.31h-1.61v-4.1c0-.57-.08-.97-.25-1.21-.17-.23-.45-.35-.83-.35-.3 0-.56.08-.79.22-.23.15-.49.36-.78.64v4.8h-1.61zm7.37 6.45c0-.56.09-1.06.26-1.51.18-.45.42-.83.71-1.14.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.36c.07.62.29 1.1.65 1.44.36.33.82.5 1.38.5.29 0 .57-.04.83-.13s.51-.21.76-.37l.55 1.01c-.33.21-.69.39-1.09.53-.41.14-.83.21-1.26.21-.48 0-.92-.08-1.34-.25-.41-.16-.76-.4-1.07-.7-.31-.31-.55-.69-.72-1.13-.18-.44-.26-.95-.26-1.52zm4.6-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.07.45-.31.29-.5.73-.58 1.3zm2.5.62c0-.57.09-1.08.28-1.53.18-.44.43-.82.75-1.13s.69-.54 1.1-.71c.42-.16.85-.24 1.31-.24.45 0 .84.08 1.17.23s.61.34.85.57l-.77 1.02c-.19-.16-.38-.28-.56-.37-.19-.09-.39-.14-.61-.14-.56 0-1.01.21-1.35.63-.35.41-.52.97-.52 1.67 0 .69.17 1.24.51 1.66.34.41.78.62 1.32.62.28 0 .54-.06.78-.17.24-.12.45-.26.64-.42l.67 1.03c-.33.29-.69.51-1.08.65-.39.15-.78.23-1.18.23-.46 0-.9-.08-1.31-.24-.4-.16-.75-.39-1.05-.7s-.53-.69-.7-1.13c-.17-.45-.25-.96-.25-1.53zm6.91-6.45h1.58v6.17h.05l2.54-3.16h1.77l-2.35 2.8 2.59 4.07h-1.75l-1.77-2.98-1.08 1.23v1.75h-1.58zm13.69 1.27c-.25-.11-.5-.17-.75-.17-.58 0-.87.39-.87 1.16v.75h1.34v1.27h-1.34v5.6h-1.61v-5.6h-.92v-1.2l.92-.07v-.72c0-.35.04-.68.13-.98.08-.31.21-.57.4-.79s.42-.39.71-.51c.28-.12.63-.18 1.04-.18.24 0 .48.02.69.07.22.05.41.1.57.17zm.48 5.18c0-.57.09-1.08.27-1.53.17-.44.41-.82.72-1.13.3-.31.65-.54 1.04-.71.39-.16.8-.24 1.23-.24s.84.08 1.24.24c.4.17.74.4 1.04.71s.54.69.72 1.13c.19.45.28.96.28 1.53s-.09 1.08-.28 1.53c-.18.44-.42.82-.72 1.13s-.64.54-1.04.7-.81.24-1.24.24-.84-.08-1.23-.24-.74-.39-1.04-.7c-.31-.31-.55-.69-.72-1.13-.18-.45-.27-.96-.27-1.53zm1.65 0c0 .69.14 1.24.43 1.66.28.41.68.62 1.18.62.51 0 .9-.21 1.19-.62.29-.42.44-.97.44-1.66 0-.7-.15-1.26-.44-1.67-.29-.42-.68-.63-1.19-.63-.5 0-.9.21-1.18.63-.29.41-.43.97-.43 1.67zm6.48-3.44h1.33l.12 1.21h.05c.24-.44.54-.79.88-1.02.35-.24.7-.36 1.07-.36.32 0 .59.05.78.14l-.28 1.4-.33-.09c-.11-.01-.23-.02-.38-.02-.27 0-.56.1-.86.31s-.55.58-.77 1.1v4.2h-1.61zm-47.87 15h1.61v4.1c0 .57.08.97.25 1.2.17.24.44.35.81.35.3 0 .57-.07.8-.22.22-.15.47-.39.73-.73v-4.7h1.61v6.87h-1.32l-.12-1.01h-.04c-.3.36-.63.64-.98.86-.35.21-.76.32-1.24.32-.73 0-1.27-.24-1.61-.71-.33-.47-.5-1.14-.5-2.02zm9.46 7.43v2.16h-1.61v-9.59h1.33l.12.72h.05c.29-.24.61-.45.97-.63.35-.17.72-.26 1.1-.26.43 0 .81.08 1.15.24.33.17.61.4.84.71.24.31.41.68.53 1.11.13.42.19.91.19 1.44 0 .59-.09 1.11-.25 1.57-.16.47-.38.85-.65 1.16-.27.32-.58.56-.94.73-.35.16-.72.25-1.1.25-.3 0-.6-.07-.9-.2s-.59-.31-.87-.56zm0-2.3c.26.22.5.37.73.45.24.09.46.13.66.13.46 0 .84-.2 1.15-.6.31-.39.46-.98.46-1.77 0-.69-.12-1.22-.35-1.61-.23-.38-.61-.57-1.13-.57-.49 0-.99.26-1.52.77zm5.87-1.69c0-.56.08-1.06.25-1.51.16-.45.37-.83.65-1.14.27-.3.58-.54.93-.71s.71-.25 1.08-.25c.39 0 .73.07 1 .2.27.14.54.32.81.55l-.06-1.1v-2.49h1.61v9.88h-1.33l-.11-.74h-.06c-.25.25-.54.46-.88.64-.33.18-.69.27-1.06.27-.87 0-1.56-.32-2.07-.95s-.76-1.51-.76-2.65zm1.67-.01c0 .74.13 1.31.4 1.7.26.38.65.58 1.15.58.51 0 .99-.26 1.44-.77v-3.21c-.24-.21-.48-.36-.7-.45-.23-.08-.46-.12-.7-.12-.45 0-.82.19-1.13.59-.31.39-.46.95-.46 1.68zm6.35 1.59c0-.73.32-1.3.97-1.71.64-.4 1.67-.68 3.08-.84 0-.17-.02-.34-.07-.51-.05-.16-.12-.3-.22-.43s-.22-.22-.38-.3c-.15-.06-.34-.1-.58-.1-.34 0-.68.07-1 .2s-.63.29-.93.47l-.59-1.08c.39-.24.81-.45 1.28-.63.47-.17.99-.26 1.54-.26.86 0 1.51.25 1.93.76s.63 1.25.63 2.21v4.07h-1.32l-.12-.76h-.05c-.3.27-.63.48-.98.66s-.73.27-1.14.27c-.61 0-1.1-.19-1.48-.56-.38-.36-.57-.85-.57-1.46zm1.57-.12c0 .3.09.53.27.67.19.14.42.21.71.21.28 0 .54-.07.77-.2s.48-.31.73-.56v-1.54c-.47.06-.86.13-1.18.23-.31.09-.57.19-.76.31s-.33.25-.41.4c-.09.15-.13.31-.13.48zm6.29-3.63h-.98v-1.2l1.06-.07.2-1.88h1.34v1.88h1.75v1.27h-1.75v3.28c0 .8.32 1.2.97 1.2.12 0 .24-.01.37-.04.12-.03.24-.07.34-.11l.28 1.19c-.19.06-.4.12-.64.17-.23.05-.49.08-.76.08-.4 0-.74-.06-1.02-.18-.27-.13-.49-.3-.67-.52-.17-.21-.3-.48-.37-.78-.08-.3-.12-.64-.12-1.01zm4.36 2.17c0-.56.09-1.06.27-1.51s.41-.83.71-1.14c.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.37c.08.62.29 1.1.65 1.44.36.33.82.5 1.38.5.3 0 .58-.04.84-.13.25-.09.51-.21.76-.37l.54 1.01c-.32.21-.69.39-1.09.53s-.82.21-1.26.21c-.47 0-.92-.08-1.33-.25-.41-.16-.77-.4-1.08-.7-.3-.31-.54-.69-.72-1.13-.17-.44-.26-.95-.26-1.52zm4.61-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.08.45-.31.29-.5.73-.57 1.3zm3.01 2.23c.31.24.61.43.92.57.3.13.63.2.98.2.38 0 .65-.08.83-.23s.27-.35.27-.6c0-.14-.05-.26-.13-.37-.08-.1-.2-.2-.34-.28-.14-.09-.29-.16-.47-.23l-.53-.22c-.23-.09-.46-.18-.69-.3-.23-.11-.44-.24-.62-.4s-.33-.35-.45-.55c-.12-.21-.18-.46-.18-.75 0-.61.23-1.1.68-1.49.44-.38 1.06-.57 1.83-.57.48 0 .91.08 1.29.25s.71.36.99.57l-.74.98c-.24-.17-.49-.32-.73-.42-.25-.11-.51-.16-.78-.16-.35 0-.6.07-.76.21-.17.15-.25.33-.25.54 0 .14.04.26.12.36s.18.18.31.26c.14.07.29.14.46.21l.54.19c.23.09.47.18.7.29s.44.24.64.4c.19.16.34.35.46.58.11.23.17.5.17.82 0 .3-.06.58-.17.83-.12.26-.29.48-.51.68-.23.19-.51.34-.84.45-.34.11-.72.17-1.15.17-.48 0-.95-.09-1.41-.27-.46-.19-.86-.41-1.2-.68z" fill="#535353"/></g></svg>\" width=\"57\"/><h3>Cite this article</h3><p>Shen, Y., Ding, X. Angiotensinogen: a new era beyond lactate as a biomarker?. <i>Crit Care</i> <b>28</b>, 398 (2024). https://doi.org/10.1186/s13054-024-05164-y</p><p>Download citation<svg aria-hidden=\"true\" focusable=\"false\" height=\"16\" role=\"img\" width=\"16\"><use xlink:href=\"#icon-eds-i-download-medium\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"></use></svg></p><ul data-test=\"publication-history\"><li><p>Received<span>: </span><span><time datetime=\"2024-11-05\">05 November 2024</time></span></p></li><li><p>Accepted<span>: </span><span><time datetime=\"2024-11-08\">08 November 2024</time></span></p></li><li><p>Published<span>: </span><span><time datetime=\"2024-12-02\">02 December 2024</time></span></p></li><li><p>DOI</abbr><span>: </span><span>https://doi.org/10.1186/s13054-024-05164-y</span></p></li></ul><h3>Share this article</h3><p>Anyone you share the following link with will be able to read this content:</p><button data-track=\"click\" data-track-action=\"get shareable link\" data-track-external=\"\" data-track-label=\"button\" type=\"button\">Get shareable link</button><p>Sorry, a shareable link is not currently available for this article.</p><p data-track=\"click\" data-track-action=\"select share url\" data-track-label=\"button\"></p><button data-track=\"click\" data-track-action=\"copy share url\" data-track-external=\"\" data-track-label=\"button\" type=\"button\">Copy to clipboard</button><p> Provided by the Springer Nature SharedIt content-sharing initiative </p>","PeriodicalId":10811,"journal":{"name":"Critical Care","volume":"260 1","pages":""},"PeriodicalIF":8.8000,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical Care","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13054-024-05164-y","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}
引用次数: 0

Abstract

Dear editor

In a recent brief report [1], Dr.Chappell and colleagues compared the predictive value of angiotensinogen, renin, and lactate for 30-day mortality in patients with sepsis or septic shock. The study included a total of 103 sepsis patients. The results showed that serum angiotensinogen concentration had a stronger association with mortality than either serum renin or lactate, suggesting that angiotensinogen may serve as a clinical predictor superior to lactate. We believe several points should be noted when interpreting these findings.

First, lactate is widely recognized as an important biomarker in critically ill patients, primarily reflecting an imbalance in tissue oxygen supply and consumption, which is commonly used to assess tissue perfusion and disease severity in septic shock. However, although this study included patients with sepsis or septic shock, we observed that the baseline systolic blood pressure in both the survival and non-survival groups was approximately 100 mmHg (survival group: 102.1 ± 23.5; non-survival group: 106.0 ± 21.9, p = 0.464), indicating that these patients were not in a state of severe shock or, at the very least, retained a degree of hemodynamic stability. Additionally, the baseline lactate levels were also relatively low and similar between the two groups (survival group: 2.6 [1.8–3.8]; non-survival group: 2.2 [1.6–6.1], p = 0.629). This raises the question of whether the study sample might skew toward a less severe sepsis population, which could influence the relative performance of angiotensinogen and lactate as predictive markers (as patients with relatively stable circulation tend to have normal lactate levels).

Moreover, this study found no significant difference in survival analysis between high and low lactate groups, which is inconsistent with previous findings in septic shock [2,3,4]. This lack of difference may be attributed to specific characteristics of the patient cohort or sample heterogeneity, which may limit the generalizability of this study’s findings to sepsis patients.

Future studies with larger, more diverse sepsis cohorts are needed to validate these findings and further explore the potential of angiotensinogen as a routine prognostic marker in sepsis or septic shock. Given lactate’s established role in assessing sepsis severity and predicting outcomes, future research should also investigate whether angiotensinogen can complement lactate or other established biomarkers to provide additional prognostic value. Also, longitudinal studies could help clarify the dynamic changes in angiotensinogen levels over time and their correlation with patient outcomes, offering a more comprehensive understanding of angiotensinogen’s role in the complex pathophysiology of sepsis.

Finally, we extend our gratitude to Dr. Chappell and colleagues for their valuable work, and we hope our perspectives contribute to a deeper understanding of these findings.

No datasets were generated or analysed during the current study.

  1. Chappell MC, Schaich CL, Busse LW, Martin GS, Sevransky JE, Hinson JK, Khanna AK, Vitamin C. Stronger association of intact angiotensinogen with mortality than lactate or renin in critical illness: post-hoc analysis from the VICTAS trial. Crit Care. 2024;28(1):333.

    Article PubMed PubMed Central Google Scholar

  2. Zampieri FG, Damiani LP, Bakker J, Ospina-Tascon GA, Castro R, Cavalcanti AB, Hernandez G. Effects of a Resuscitation Strategy Targeting Peripheral Perfusion Status versus serum lactate levels among patients with septic shock. A bayesian reanalysis of the ANDROMEDA-SHOCK Trial. Am J Respir Crit Care Med. 2020;201(4):423–9.

    Article CAS PubMed Google Scholar

  3. Han X, Edelson DP, Snyder A, Pettit N, Sokol S, Barc C, Howell MD, Churpek MM. Implications of Centers for Medicare & Medicaid Services Severe Sepsis and septic shock early management bundle and initial lactate measurement on the management of Sepsis. Chest. 2018;154(2):302–8.

    Article PubMed PubMed Central Google Scholar

  4. Houwink AP, Rijkenberg S, Bosman RJ, van der Voort PH. The association between lactate, mean arterial pressure, central venous oxygen saturation and peripheral temperature and mortality in severe sepsis: a retrospective cohort analysis. Crit Care. 2016;20:56.

    Article PubMed PubMed Central Google Scholar

Download references

Not applicable.

None.

Authors and Affiliations

  1. Department of Intensive Care, Zhejiang Hospital, No. 1229, Gudun Road, Hangzhou, 310013, Zhejiang, People’s Republic of China

    Yanfei Shen

  2. The Second Clinical Medical College of Zhejiang, Chinese Medical University, Hangzhou, 310053, Zhejiang, China

    Xinyuan Ding

Authors
  1. Yanfei ShenView author publications

    You can also search for this author in PubMed Google Scholar

  2. Xinyuan DingView author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Dr. Xinyuan Ding raised the clinical issue and Dr. Yanfei Shen wrote the letter. All authors have reviewed and approved the letter.

Corresponding author

Correspondence to Yanfei Shen.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

Reprints and permissions

Abstract Image

Cite this article

Shen, Y., Ding, X. Angiotensinogen: a new era beyond lactate as a biomarker?. Crit Care 28, 398 (2024). https://doi.org/10.1186/s13054-024-05164-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13054-024-05164-y

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
血管紧张素原:超越乳酸作为生物标志物的新时代?
通讯作者沈燕飞通信。对参与者的伦理批准和同意不适用。发表同意不适用。利益竞争作者声明没有利益竞争。出版方声明:对于已出版地图的管辖权要求和机构关系,普林格·自然保持中立。开放获取本文遵循知识共享署名-非商业-非衍生品4.0国际许可协议,该协议允许以任何媒介或格式进行非商业用途、共享、分发和复制,只要您适当注明原作者和来源,提供知识共享许可协议的链接,并注明您是否修改了许可材料。根据本许可协议,您无权分享源自本文或其部分内容的改编材料。本文中的图像或其他第三方材料包含在文章的知识共享许可协议中,除非在材料的署名中另有说明。如果材料未包含在文章的知识共享许可中,并且您的预期用途不被法律法规允许或超过允许的用途,您将需要直接获得版权所有者的许可。要查看该许可的副本,请访问http://creativecommons.org/licenses/by-nc-nd/4.0/.Reprints和permissionsCite这篇文章:血管紧张素原:超越乳酸作为生物标志物的新时代?重症监护28,398(2024)。https://doi.org/10.1186/s13054-024-05164-yDownload citation:收稿日期:2024年11月05日接受日期:2024年11月08日发布日期:2024年12月02日doi: https://doi.org/10.1186/s13054-024-05164-yShare这篇文章任何你分享以下链接的人都可以阅读到这篇文章:获取可共享链接对不起,本文目前没有可共享链接。复制到剪贴板由施普林格自然共享内容倡议提供
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Critical Care
Critical Care 医学-危重病医学
CiteScore
20.60
自引率
3.30%
发文量
348
审稿时长
1.5 months
期刊介绍: Critical Care is an esteemed international medical journal that undergoes a rigorous peer-review process to maintain its high quality standards. Its primary objective is to enhance the healthcare services offered to critically ill patients. To achieve this, the journal focuses on gathering, exchanging, disseminating, and endorsing evidence-based information that is highly relevant to intensivists. By doing so, Critical Care seeks to provide a thorough and inclusive examination of the intensive care field.
期刊最新文献
Effect of an intensive care unit virtual reality intervention on relatives´ mental health distress: a multicenter, randomized controlled trial Enhancing depression risk assessment in critical care nurses: a call for quantitative modeling Clinical subtypes in critically ill patients with sepsis: validation and parsimonious classifier model development Relationship between skin microvascular blood flow and capillary refill time in critically ill patients Trendelenburg position is a reasonable alternative to passive leg raising for predicting volume responsiveness in mechanically ventilated patients in the ICU
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1